Cytomegalovirus (CMV) clinical trials at UC Health
2 research studies open to new patients
A Study of the Safety and Efficiency of Experimental Drug Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infection
open to eligible people ages 12 years and up
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.
at UCLA UC Davis
Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
open to eligible people ages 16 years and up
The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.